#evaluate(de(' #AdditionalMetaTags# '))#
Creoptix develops and markets analytical instruments for drug discovery.
Drugs work by binding to their drug target. To analyse this binding is therefore key for the pharmaceutical industry with an increasing need of higher sensitivity and the flexibility to measure a variety of samples. Based on proprietary and patented disruptive technology, Creoptix has launched and sells its first product, Creoptix WAVE, a system of instrument and disposables achieving unparalleled sensitivity in the market and offering measurements of even the most crude samples such as undiluted blood serum. This enables new applications in drug discovery but also in pharmacology and diagnostics.
Creoptix gets acquired by Malvern Panalytical to advance pharmaceutical drug development solutions (venturelab.swiss)
Creoptix joins the Malvern Panalytical team in England (startupticker.ch)
Swiss start-ups drive research around Covid-19 (startupticker.ch)
Swiss Startups Tackling Corona Virus - COVID-19 (venturelab.swiss)
The New Year resolution for startups: New executive members aboard (startupticker.ch)
Creoptix raises CHF18 million in Series C round (startupticker.ch)
Creoptix raises CHF8 million in Series C round (startupticker.ch)
Creoptix attracts Waters as corporate investor (startupticker.ch)
LeadXpro AG relies on Creoptix?s technology (startupticker.ch)
Nine hot start-ups, 400 visitors and Joe Jimenez (startupticker.ch)
Leading conference selects Creoptix for its innovation platform (startupticker.ch)
Creoptix AG announces the launch of its WAVE system (startupticker.ch)
Creoptix AG closes CHF 3 Million Series A Financing (startupticker.ch)
First sales
CTI Label